Third Phase in Polymer Drug Development: — Smancs as a Prototype Model Drug for Cancer Treatment —
Tumor cells are essentially identical to the normal cells of the host in view of biochemical or molecular biological events and machineries thereof. However, I see a great difference between tumor and normal cells exists at the tissue level, particularly in tumor blood vessels. Therefore, it is a wise choice to develop a drug which will seek and find this unique character at the vascular level. Macromolecules with biocompatible nature can be best utilized in this respect since we found that they leak out at the tumor blood vessels more selectively and remain uncleared in the tumor tissues for long time: i.e. extravasation into interstitial tumor tissue is much enhanced, but the clearance from tumor is greatly suppressed compared to the normal tissues. I coined this phenomenon as enhanced permeability and retention (EPR) effect of macromolecules and lipids in solid tumor[2–5].
KeywordsTumor Blood Vessel Macromolecular Drug Biocompatible Nature Bone Marrow Delivery Macromolecular Therapeutics
Unable to display preview. Download preview PDF.
- 1.Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46: 6387–6392Google Scholar
- 3.Maeda H, Matsumura Y (1989) Tumoritropic and lymphotropic principle of macromolecular drug. Crit. Rev. Ther. Drug Carrier Syst. 6: 193–210Google Scholar
- 11.Iwai K, Maeda H, Konno T (1984) Use of oily contrast medium for selective drug targeting to tumor: Enhanced therapeutic effect and X-ray image. Cancer Res., 44: 2115–2121Google Scholar
- 13.Oda T, Morinaga T, Maeda H (1986) Stimulation of macrophage by polyanions and its conjugated proteins and effect on cell membrane. Proc. Soc. Exp. Biol. Med. 181: 9–17Google Scholar
- 16.Kimura M, Konno T, Oda T, Maeda H, Miyauchi Y (1993) Intracavitary treatment of malignant ascitic carcinomatosis with oily anticancer agents in rats. Anticancer Res. 13: 1287–1292Google Scholar
- 17.Seymour LW, Miyamoto Y, Maeda H, Brereton M, Strohalm J, Ulbrich K, Duncan R (1995) Influence of molecular weight on passive tumor accumulation of soluble macromolecular drug carrier. Eur. J. Cancer (May, in press)Google Scholar
- 19.Maeda H, Miyamoto Y (1994) SMANCS approach — Oily formulations of protein drug for arterial injection and oral administration. In: Drug Absorption Enhancement. H.G.de Boer (ed) Harwood Academic Pubis, pp 221–247Google Scholar